Business
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its
About this update from Caribou Biosciences, Inc.
[{"type":"image","alt":"Caribou Biosciences, Inc.","displaySize":"","headline":null,"caption":"Caribou Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rnd4qeRJ_xjp9Qy6VyL25w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/daefc0c372fe0c4b67822f8b9179087c","width":300,"height":74}},"lazy":false},{"type":"text","content":"-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 --","length":98,"tagName":"p"},{"type":"text","content":"-- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 --","length":140,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncology clinical programs CB-010 and CB-011 with data disclosure for each planned for H2 2025.","length":366,"tagName":"p"},{"type":"text","content":"“Caribou’s two lead Phase 1 clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to demonstrate encouraging efficacy and have the potential to benefit individuals living with hematologic malignancies,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “We look forward to disclosing two robust clinical datasets from these programs in the second half of this year as we focus on our goal to deliver these off-the-shelf allogeneic CAR-T cell therapies that offer the potential for broad access and rapid availability to both patients and healthcare systems.”","length":604,"tagName":"p"},{"type":"text","content":"Clinical highlightsCB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma","length":116,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Caribou is enrolling a 20-patient confirmatory cohort using the Company’s HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL) patients. In H2 ...